BioCryst losses soar to $32.7M in 2010, including $9.1M in 4Q
Durham County, N.C. —
Boosted by federal support for development of a pandemic flu vaccine, Biocryst reported a $13.5 million loss a year earlier.
In the fourth quarter, the firm reported a loss of $9.1 million, or 20 cents per share. A year earlier, boosted by federal payments for the development of a pandemic vaccine, BioCryst reported a $15.2 million quarterly profit.
The company's research and development costs climbed to $82.5 million in 2010 from $72.3 million a year earlier. General operating expenses also increased, hitting $14.2 million compared to $11.5 million in 2009.
Revenues fell to $63.5 million from $74.6 million in 2009.
For the full earnings report and a recap of 2010, read here.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.
Please Log In to add a comment.
Best of TechWire Insider
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution
- Can Barley's bark win Super Bowl gold for Durham startup?
- Tech guru Mossberg changes gears, praises Republic Wireless
- Survey explodes myth of the poor VC-backed entrepreneur
- Analyze this: SAS steps up education commitment with Teradata deal
- Web Foundation report reflects concerns about US security state